TY - JOUR
T1 - MIP-1α/CCL3-expressing basophil-lineage cells drive the leukemic hematopoiesis of chronic myeloid leukemia in mice
AU - Baba, Tomohisa
AU - Tanabe, Yamato
AU - Yoshikawa, Soichiro
AU - Yamanishi, Yoshinori
AU - Morishita, Soji
AU - Komatsu, Norio
AU - Karasuyama, Hajime
AU - Hirao, Atsushi
AU - Mukaida, Naofumi
N1 - Funding Information:
This work was supported in part by a Project for the Development of Innovative Research on Cancer Therapeutics (P-DIRECT, Japan Agency for Medical Research and Development), KAKENHI grant 25460492 (Japan Society for the Promotion of Science), and the Open Partnership Joint Project (Japan Society for the Promotion of Science).
Publisher Copyright:
© 2016 by The American Society of Hematology.
PY - 2016/5/26
Y1 - 2016/5/26
N2 - Basophilia is a frequently observed hematological abnormality in chronic myeloid leukemia (CML), but its pathophysiological roles are undefined. We previously demonstrated that an inflammatory chemokine, CCL3, preferentially acts on normal hematopoietic stem/progenitor cells and crucially contributes to the maintenance of leukemia initiating cells (LICs) in bone marrow (BM) during the initiation process of CML. However, the major cellular source of CCL3 in BM and the precise mechanism of CCL3-mediated maintenance of LICs remain to be investigated. To delineate the cellular process facilitating this CCL3-mediated crosstalk between normal and leukemic hematopoiesis, we precisely examined CCL3-expressing cells and their functions in both normal hematopoiesis and CML leukemogenesis. Herein, we demonstrate that basophils can constitutively express CCL3 to negatively regulate the normal hematopoietic process, especially hematopoietic reconstitution after BM transplantation. Moreover, CCL3-expressing basophil-like leukemia cells were found to accumulate in CML BM and supported the predominant expansion of LICs therein. These observations suggest that intra-BM basophil expansion can favor leukemia-tropic hematopoiesis in CML by providing CCL3, a potent inhibitor of normal hematopoiesis and that basophil-derived CCL3 may be a novel target molecule for the treatment of CML.
AB - Basophilia is a frequently observed hematological abnormality in chronic myeloid leukemia (CML), but its pathophysiological roles are undefined. We previously demonstrated that an inflammatory chemokine, CCL3, preferentially acts on normal hematopoietic stem/progenitor cells and crucially contributes to the maintenance of leukemia initiating cells (LICs) in bone marrow (BM) during the initiation process of CML. However, the major cellular source of CCL3 in BM and the precise mechanism of CCL3-mediated maintenance of LICs remain to be investigated. To delineate the cellular process facilitating this CCL3-mediated crosstalk between normal and leukemic hematopoiesis, we precisely examined CCL3-expressing cells and their functions in both normal hematopoiesis and CML leukemogenesis. Herein, we demonstrate that basophils can constitutively express CCL3 to negatively regulate the normal hematopoietic process, especially hematopoietic reconstitution after BM transplantation. Moreover, CCL3-expressing basophil-like leukemia cells were found to accumulate in CML BM and supported the predominant expansion of LICs therein. These observations suggest that intra-BM basophil expansion can favor leukemia-tropic hematopoiesis in CML by providing CCL3, a potent inhibitor of normal hematopoiesis and that basophil-derived CCL3 may be a novel target molecule for the treatment of CML.
UR - http://www.scopus.com/inward/record.url?scp=84982792381&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84982792381&partnerID=8YFLogxK
U2 - 10.1182/blood-2015-10-673087
DO - 10.1182/blood-2015-10-673087
M3 - Article
C2 - 27006388
AN - SCOPUS:84982792381
SN - 0006-4971
VL - 127
SP - 2607
EP - 2617
JO - Blood
JF - Blood
IS - 21
ER -